A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 2, 2008, Pages 139-145

  Katiyar, S K ^a   Bihari, S ^a   Prakash, S ^a,b   Mamtani, M ^b   Kulkarni, Hemant ^b,c  

^a GSVM MEDICAL COLLEGE   (India)

^b Lata Medical Research Foundation   (India)

^c NONE   (United States)

Author keywords

Isoniazid; Multidrug resistant tuberculosis; Randomised controlled trial

Indexed keywords

ISONIAZID; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SPUTUM CULTURE; TERTIARY HEALTH CARE; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ADULT; ANTITUBERCULAR AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 38949175355     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Dye C, Espinal M A, Watt C J, Mbiaga C, Williams B G. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002; 185: 1197-1202.
2. Dye C, Williams B G, Espinal M A, Raviglione M C. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002; 295: 2042-2046.
3. Shah N S, Wright A, Bai G H, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13: 380-387.
4. Atun R A, Lebcir R, Drobniewski F, Coker R J. Impact of an effective multidrug-resistant tuberculosis control programme in the setting of an immature HIV epidemic: system dynamics simulation model. Int J STD AIDS 2005; 16: 560-570.
5. Atun R A, Lebcir R M, McKee M, Habicht J, Coker R J. Impact of joined-up HIV harm reduction and multidrug resistant tuberculosis control programmes in Estonia: system dynamics simulation model. Health Policy 2007; 81: 207-217.
6. Holtz T H, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006; 144: 650-659.
7. Kawai V, Soto G, Gilman R H, et al. Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. Am J Trop Med Hyg 2006; 75: 1027-1033.
8. Palmero D, Cusmano L, Bucci Z, Romano M, Ruano S, Waisman J. [Infectiousness and virulence of multidrug-resistant and drug susceptible tuberculosis in adult contacts]. Medicina (Buenos Aires) 2002; 62: 221-225. [Spanish]
9. Fisher M. Diagnosis of MDR-TB: a developing world problem on a developed world budget. Expert Rev Mol Diagn 2002; 2: 151-159.
10. Resch S C, Salomon J A, Murray M, Weinstein M C. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 2006; 3: e241.
11. Drobniewski F, Balabanova Y, Coker R. Clinical features, diagnosis, and management of multiple drug-resistant tuberculosis since 2002. Curr Opin Pulm Med 2004; 10: 211-217.
12. Iseman M D, Goble M. Multidrug-resistant tuberculosis. N Engl J Med 1996; 334: 267; author reply 268-269.
13. Park S K, Kim C T, Song S D. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis 1998; 2: 877-884.
14. Pablos-Mendez A, Gowda D K, Frieden T R. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Bull World Health Organ 2002; 80: 489-495; discussion 495-500.
15. Tupasi T E, Quelapio M I, Orillaza R B, et al. DOTS-Plus for multidrug-resistant tuberculosis in the Philippines: global assistance urgently needed. Tuberculosis (Edinburgh) 2003; 83: 52-58.
16. Park S K, Lee W C, Lee D H, Mitnick C D, Han L, Seung K J. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 2004; 8: 361-368.
17. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55: 301-305.
18. Prasad R. Management of multidrug-resistant tuberculosis: practitioner's view point. Indian J Tuberc 2007; 54: 3-11.
19. Victor T C, Warren R, Butt J L, et al. Genome and MIC stability in Mycobacterium tuberculosis and indications for continuation of use of isoniazid in multidrug-resistant tuberculosis. J Med Microbiol 1997; 46: 847-857.
20. Schaaf H S, Victor T C, Engelke E, et al. Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children. Eur J Clin Microbiol Infect Dis 2007; 26: 203-205.
21. Subhash H S, Ashwin I, Jesudason M V, et al. Clinical characteristics and treatment response among patients with multidrug-resistant tuberculosis: a retrospective study. Indian J Chest Dis Allied Sci 2003; 45: 97-103.
22. Dupont W P, Plummer W D. Power and sample size calculations: A review and computer program. Control Clin Trials 1990; 11: 116-128.
23. Ormerod L P. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br Med Bull 2005; 73-74: 17-24.
24. Garrigo M, Aragon L M, Alcaide F, et al. Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2007; 45: 1766-1770.
25. Gil-Setas A, Torroba L, Fernandez J L, Martinez-Artola V, Olite J. Evaluation of the MB/BacT system compared with Middlebrook 7H11 and Löwenstein-Jensen media for detection and recovery of mycobacteria from clinical specimens. Clin Microbiol Infect 2004; 10: 224-228.
26. Attia J, Page J, Heller R F, Dobson A J. Impact numbers in health policy decisions. J Epidemiol Community Health 2002; 56: 600-605.
27. Frieden T R, Sherman L F, Maw K L, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996; 276: 1229-1235.
28. Moulding T S, Le H Q, Rikleen D, Davidson P. Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin. Int J Tuberc Lung Dis 2004; 8: 743-748.
29. Van Deun A, Salim M A, Das A P, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004; 8: 560-567.
30. Klemens S P, DeStefano M S, Cynamon M H. Therapy of multidrug-resistant tuberculosis: lessons from studies with mice. Antimicrob Agents Chemother 1993; 37: 2344-2347.
31. Fraser A, Paul M, Attamna A, Leibovici L. Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev 2006: CD005435.
32. Quy H T, Buu T N, Cobelens F G, Lan N T, Lambregts C S, Borgdorff M W. Drug resistance among smear-positive tuberculosis patients in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 2006; 10: 160-166.